Mitralign Lands $35,000,000 Series D Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    3 Highwood Drive Tewksbury, MA 01876
  • Company Description
    We are currently developing an innovative, catheter-based mitral valve repair system that not only provides an alternative to open heart surgery but emulates the traditional surgical repair technique.

    The condition treated, mitral valve regurgitation (MR), is common in patients with Congestive Heart Failure. Clinical studies have proven that MR significantly increases the risk of mortality in patients afflicted with CHF, a disease affecting 25 Million worldwide. Studies hence recommend earlier treatment of MR in these patients.

  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the Series D financing will support completing the CE Mark study, securing the CE Mark, and initiating sales in the EU.
  • M&A Terms
  • Venture Investor
    Forbion Capital Partners
  • Venture Investor
    Saints Capital
  • Venture Investor
    Oxford Bioscience Partners
  • Venture Investor
    Triathlon Medical Ventures
  • Venture Investor
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    Oakwood Medical Investors
  • Venture Investor
    Palisade Capital Management
  • Venture Investor
    Giza Capital

Trending on Xconomy